VectivBio Holding AG (VECT)
VectivBio Holding AG operates in the Biotechnology industry of the Healthcare sector, headquartered in Basel, CH. The stock last traded at $16.87, up 0.12% on the session, giving a market capitalisation of $1.06B. On trailing twelve-month figures it carries a trailing P/E of -7.96, a net margin of -342.8%. Its beta of 0.10 implies it has historically moved less than the broad market.
VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to identifying, developing, and commercializing treatments for severe rare medical conditions. The company's primary therapeutic focus is apraglutide, a prolonged-acting synthetic peptide analog of glucagon-like peptide-2. This compound is currently in a Phase III clinical trial for individuals with short bowel syndrome-intestinal failure (SBS-IF), and is also being evaluated in a Phase II clinical trial for SBS-IF patients with colon-in-continuity anatomy. Furthermore, apraglutide is undergoing a Phase II clinical study for patients experiencing steroid-refractory gastrointestinal acute graft-versus-host disease (aGvHD). Founded in 2019, VectivBio's corporate headquarters are situated in Basel, Switzerland.
VectivBio Holding AG is most often compared with the following Healthcare names: